150
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Enhanced ubiquitin-dependent degradation by Nedd4 protects against α-synuclein accumulation and toxicity in animal models of Parkinson's disease

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Parkinson's disease is a neurodegenerative disorder, characterized by accumulation and misfolding of α-synuclein. Although the level of α-synuclein in neurons is fundamentally linked to the onset of neurodegeneration, multiple pathways have been implicated in its degradation, and it remains unclear which are the critical ubiquitination enzymes that protect against α-synuclein accumulation in vivo. The ubiquitin ligase Nedd4 targets α-synuclein to the endosomal–lysosomal pathway in cultured cells. Here we asked whether Nedd4-mediated degradation protects against α-synuclein-induced toxicity in the Drosophila and rodent models of Parkinson's disease. We show that overexpression of Nedd4 can rescue the degenerative phenotype from ectopic expression of α-synuclein in the Drosophila eye. Overexpressed Nedd4 in the Drosophila brain prevented the α-synuclein-induced locomotor defect whereas reduction in endogenous Nedd4 by RNAi led to worsening motor function and increased loss of dopaminergic neurons. Accordingly, AAV-mediated expression of wild-type but not the catalytically inactive Nedd4 decreased the α-synuclein-induced dopaminergic cell loss in the rat substantia nigra and reduced α-synuclein accumulation. Collectively, our data in two evolutionarily distant model organisms strongly suggest that Nedd4 is a modifier of α-synuclein pathobiology and thus a potential target for neuroprotective therapies.

          Highlights

          • Nedd4 rescues the α-synuclein-induced rough-eye phenotype.

          • Nedd4 prevents the α-synuclein-induced locomotor defect in the Drosophila brain.

          • Overexpressed Nedd4 promotes α-synuclein degradation in vivo.

          • Nedd4 knockdown increases the α-synuclein-induced loss of dopaminergic neurons.

          • Nedd4 decreases dopaminergic cell loss in the rat substantia nigra.

          Related collections

          Most cited references20

          • Record: found
          • Abstract: found
          • Article: not found

          Physiological functions of the HECT family of ubiquitin ligases.

          The ubiquitylation of proteins is carried out by E1, E2 and E3 (ubiquitin ligase) enzymes, and targets them for degradation or for other cellular fates. The HECT enzymes, including Nedd4 family members, are a major group of E3 enzymes that dictate the specificity of ubiquitylation. In addition to ubiquitylating proteins for degradation by the 26S proteasome, HECT E3 enzymes regulate the trafficking of many receptors, channels, transporters and viral proteins. The physiological functions of the yeast HECT E3 ligase Rsp5 are the best known, but the functions of HECT E3 enyzmes in metazoans are now becoming clearer from in vivo studies.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Dopamine covalently modifies and functionally inactivates parkin.

            Inherited mutations in PARK2, the gene encoding parkin, cause selective degeneration of catecholaminergic neurons in the substantia nigra and locus coeruleus of the brainstem, resulting in early-onset parkinsonism. But the role of parkin in common, sporadic forms of Parkinson disease remains unclear. Here we report that the neurotransmitter dopamine covalently modifies parkin in living dopaminergic cells, a process that increases parkin insolubility and inactivates its E3 ubiquitin ligase function. In the brains of individuals with sporadic Parkinson disease, we observed decreases in parkin solubility consistent with its functional inactivation. Using a new biochemical method, we detected catechol-modified parkin in the substantia nigra but not other regions of normal human brain. These findings show a vulnerability of parkin to modification by dopamine, the principal transmitter lost in Parkinson disease, suggesting a mechanism for the progressive loss of parkin function in dopaminergic neurons during aging and sporadic Parkinson disease.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein.

              Genome-wide screens were performed in yeast to identify genes that enhance the toxicity of a mutant huntingtin fragment or of alpha-synuclein. Of 4850 haploid mutants containing deletions of nonessential genes, 52 were identified that were sensitive to a mutant huntingtin fragment, 86 that were sensitive to alpha-synuclein, and only one mutant that was sensitive to both. Genes that enhanced toxicity of the mutant huntingtin fragment clustered in the functionally related cellular processes of response to stress, protein folding, and ubiquitin-dependent protein catabolism, whereas genes that modified alpha-synuclein toxicity clustered in the processes of lipid metabolism and vesicle-mediated transport. Genes with human orthologs were overrepresented in our screens, suggesting that we may have discovered conserved and nonoverlapping sets of cell-autonomous genes and pathways that are relevant to Huntington's disease and Parkinson's disease.
                Bookmark

                Author and article information

                Contributors
                Journal
                Neurobiol Dis
                Neurobiol. Dis
                Neurobiology of Disease
                Academic Press
                0969-9961
                1095-953X
                1 April 2014
                April 2014
                : 64
                : 100
                : 79-87
                Affiliations
                [a ]Nuffield Department of Clinical Neurosciences, University of Oxford, UK
                [b ]Oxford Parkinson's Disease Centre, University of Oxford, UK
                [c ]MRC Functional Genomics Unit, Department of Physiology, Anatomy and Genetics, University of Oxford, UK
                [d ]Neuroregeneration Research Institute, McLean Hospital, Harvard Medical School, USA
                [e ]Department of Cell Biology, Harvard Medical School, USA
                Author notes
                [* ]Corresponding author at: Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK. Fax: + 44 1865 234699. george.tofaris@ 123456ndcn.ox.ac.uk
                [1]

                These authors contributed equally.

                Article
                S0969-9961(13)00355-0
                10.1016/j.nbd.2013.12.011
                3988924
                24388974
                043784b5-7a0d-4c98-bd3b-4c45e74aa5b7
                © 2014 The Authors

                This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).

                History
                : 20 November 2013
                : 19 December 2013
                : 24 December 2013
                Categories
                Article

                Neurosciences
                lysosome,ubiquitination,protein-degradation,endosomal-trafficking
                Neurosciences
                lysosome, ubiquitination, protein-degradation, endosomal-trafficking

                Comments

                Comment on this article